🚨 cfRNA is Here — and It’s a Game Changer! 🧬🩸 Max Diehn, MD/PhD et al., nature 2025 🔗 DOI: 10.1038/s41586-025-08834-1 👏 From one of our #ISLB awardees! 🔍 Key Highlights: ✅ RAREseq: A new method for ultrasensitive cfRNA profiling 💡 ✅ cfRNA detects early-stage NSCLC with

Great to see our team will be walking in The Banham Marsden March 2025 for The Royal Marsden Cancer Charity! Please sponsor them, I have! Every donation helps. Thanks for your support! The Royal Marsden Cancer Charity #MarsdenMarch #TheRoyalMarsdenCancerCharity march.royalmarsden.org/st/1850/t

🫁 Sunvozertinib with EGFR ex20ins 🫁 ⭐️ Genetic biomarker study ⭐️ Clinical prognosis and prediction in NSCLC ⭐️ Pie chart is the frequency of identification of ex20ins

Important awareness piece by BBC News (UK) reminding us that lung cancer is on the rise in people who have never smoked. These are different types of lung cancer and we’re still learning why they occur: radon, pollution, unknown. All of us are at risk. bbc.com/future/article…

Great to see such progress, but we have a lot of work to do for patients with lung, oesphageal, liver and pancreatic cancers. Reflects the absolute importance of #ClinicalTrial in improving outcomes CancerTrialsIreland 🌈 Trinity St James's Cancer Institute Irish Research Radiation Oncology Group Irish Cancer Society

Previous and current BTOG Chairs celebrating RoyCastleLungCancer 35th birthday behind the famous door Lung cancer screening saves lives, and 🇬🇧leads the world, but we must secure its immediate and long-term future Thank you UK Prime Minister for hosting Sanjay Popat

FDA grants accelerated approval to sunvozertinib (200mg po qd) for EGFR exon 20 insertion NSCLC after chemotherapy. In WU-KONG1B, RR 46%, mDOR 11.1m - important AEs include ILD, diarrhea, rash. Welcome addition with several others also in development. fda.gov/drugs/resource…

Consensus statement from IASLC on molecular tumor boards in lung cancer (& oncology in general). Provides framework for implementation, report standardization, case selection, quality assessment. Performance metric: changes in management based on MTB. jto.org/article/S1556-…

‘EAGLE-AI’ dig path-AI predicts EGFRmtns in NSCLC ⁦⁦Nature Medicine⁩ - assessment of 1642 H&E slides, with external (4 cohort) & prospective validation (AUC 0.83) - median turnaround time:44mins Wow OncoAlert⁩ ⁦Memorial Sloan Kettering Cancer Center⁩ #LCSM nature.com/articles/s4159…

Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052)trial leading to FDA accelerated approval avumetinib and defactinib now published Journal of Clinical Oncology Verastem Oncology First approved therapy for low grade serous ovarian cancer. Thanks all. ESGO The GOG Foundation Inc. ESMO - Eur. Oncology

Very important adjustment to FLAURA2 reimbursement in NHS England ; allowing early initiation of TKI while the chemo gets set up. Brilliant initiative by the cancer drugs fund team. BTOG #EGFR EGFR Positive Lung Cancer UK

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, Stephen V Liu, MD, Mariam Alexander & Dr. James Chih-Hsin Yang break down the data and explore clinical impact. 🎧 bit.ly/FDAexon20

New global statement in Journal of Thoracic Oncology highlights major gaps in access to Molecular Tumour Boards (MTBs) - key to personalised #lungcancer care. LuCE supports IASLC’s call for better infrastructure, wider testing & virtual MTBs. 🔗 jto.org/article/S1556-… #LCSM

Today on #WorldLungCancerDay, we reaffirm our mission to support thoracic oncology professionals and advocate for equitable, world-class care for all patients. Together, we strive to match the best survival rates globally. 💙 #WLCD2025 #LungCancerAwareness #LCSM #lungcancer

🩸 Platelets can carry tumor DNA. 🔹 Platelets – smallest yet 2nd most abundant blood cell type. 🔹New study: tumor-derived DNA found in platelets of advanced cancer patients. 🔹This cfDNA reservoir could complement plasma cfDNA, boosting detection sensitivity in low–tumor

🧬 Short-read sequencing misses up to ~11% of apparently balanced chromosomal rearrangements (ABCR). ▶️ Nico Chatron & colleagues mapped breakpoints to uncover why they were missed—often repetitive regions. ➡️ Better bioinformatic tools for alignment and calling are key to

Huge congrats David O Reilly 🇮🇪 👏 #RisingStars IASLC #WCLC2025

Ireland's representation at the IASLC #WCLC2025 in #Barcelona Growing from strength to strength! 🇮🇪 ☘️ 🫁 Huge congratulations to our very own Jarushka Naidoo (conference co-chair) on a hugely successful conference!👏👏

The RAS dam has broken! Current trials with KRAS inhibitors in progress from David S. Hong MD MD Anderson Cancer Center #AACRpan25